Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL18167021 | 0.94 | ALDH1A1 (0.41) | ALDH1A1TSHRLMNATP53L3MBTL1 | |
| Trifluoroacetic Acid SCHEMBL269102 | 0.94 | ALDH1A1 (0.41) | ALDH1A1TSHRLMNATP53L3MBTL1 | |
| Trifluoroacetic Acid SCHEMBL6356060 | 0.91 | ALDH1A1 (0.35) | ALDH1A1TSHRLMNATP53L3MBTL1 | |
| Trifluoroacetic Acid SCHEMBL3055318 | 0.88 | ALDH1A1 (0.38) | ALDH1A1TSHRLMNATP53L3MBTL1 | |
| Trifluoroacetic Acid SCHEMBL72727 | 0.87 | — | — | |
| Trifluoroacetic Acid SCHEMBL1262416 | 0.87 | — | — | |
| Trifluoroacetic Acid SCHEMBL17240187 | 0.86 | FAAH (0.34) | ALDH1A1TSHRLMNATP53 | |
| Trifluoroacetic Acid SCHEMBL29004642 | 0.85 | FAAH (0.50) | — | |
| Trifluoroacetic Acid SCHEMBL28012644 | 0.84 | ALDH1A1 (0.39) | ALDH1A1TSHRLMNATP53L3MBTL1 | |
| Trifluoroacetic Acid SCHEMBL28159900 | 0.83 | ALDH1A1 (0.41) | ALDH1A1TSHRTP53L3MBTL1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7291617-B2 | Arylamidine derivative or salt thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2007-11-06 | — | — | US | disclosed |
| EP-1037622-B1 | TAURINE DERIVATIVES USABLE IN THE TREATMENT OF RETINAL DISORDERS | KARAGEOZIAN HAMPAR (US) | 2007-04-18 | — | — | EP | disclosed |
| US-20050113424-A1 | Novel arylamidine derivative or salt thereof | TOYAMA CHEMICAL CO., LTD (JP) | 2005-05-26 | — | — | US | disclosed |
| EP-1037622-A4 | TAURINE DERIVATIVES USABLE IN THE TREATMENT OF OPHTHALMIC DISORDERS | KARAGEOZIAN HAMPAR (US) | 2002-11-06 | — | — | EP | disclosed |
| US-6391924-B1 | Taurine derivatives useable in the treatment of ophthalmic disorders | Karageozian, Hampar | 2002-05-21 | — | — | US | disclosed |
| EP-1037622-A1 | TAURINE DERIVATIVES USABLE IN THE TREATMENT OF OPHTHALMIC DISORDERS | Karageozian, Hampar (US) | 2000-09-27 | — | — | EP | disclosed |
| WO-1999029315-A1 | TAURINE DERIVATIVES USABLE IN THE TREATMENT OF OPHTHALMIC DISORDERS | KARAGEOZIAN, HAMPAR (US) | 1999-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113424-A1 | Novel arylamidine derivative or salt thereof | SLC7A1, NAT1, NACA | ALDH1A1 2071/4885TSHR 1343/4885LMNA 4640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.